SSRIs and other antidepressants
Prozac®, Zoloft®, Paxil®, Luvox®, Celexa®, Effexor®, Wellbutrin®, and other antidepressants.

DocumentsDate added

Order by : Name | Date | Hits [ Ascendant ]
file icon Intoxication Anosognosia (Medication Spellbinding) 05/15/2008
"Intoxication Anosognosia: The Spellbinding Effect of Psychiatric Drugs", Ethical Human Psychology and Psychiatry, 8, 201-215, 2006.

ABSTRACT: Why do so many individuals persist in taking psychoactive substances, including psychiatric drugs, after adverse mental and behavioral effects have become severe and even disabling? The author has previously proposed the brain-disabling principle of psychiatric treatment that all somatic psychiatric treatments impair the function of the brain and mind. Intoxication anosognosia (medication spellbinding) is an expression of this druginduced mental disability. Intoxication anosognosia causes the victim to underestimate the degree of drug-induced mental impairment, to deny the harmful role that the drug plays in the person’s altered state, and in many cases compel the individual to mistakenly believe that he or she is functioning better. In the extreme, the individual displays out-of-character compulsively destructive behaviors, including violence toward self and others.

file icon Recent US, Canadian, and British regulatory agency actions concerning antidepressant-induced harm to 01/28/2007
"Recent US, Canadian and British regulatory agency actions concerning antidepressant-induced harm to self and others: a review and analysis," International Journal of Risk & Safety in Medicine 16 (2004).
file icon Recent Regulatory Changes in Antidepressant Labels: Implicatons of Activation 01/28/2006
More focus is needed on the risk of activation or stimulation as described in the new class of warnings from the Food and Drug Administration, including anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia, hypomania, mania and other unusual changes of behavior, worsening of depression and suicidal ideation.
file icon Suicidality, violence and mania caused by selective serotonin reuptake inhibitors (SSRIs): A review 01/12/2005

Evidence from many sources confirm SSRIs commonly cause or exacerbate a wide range of abnormal mental and behavioral conditions. International Journal of Risk & Safety in Medicine 16 (2003/2004) 31-49.

file icon Copy of Breggin's Paxil product liability report in the Lacuzong case 01/12/2004
Report filed with the court stating Dr. Breggin's belief that Paxil induced Reynaldo Lacuzong to commit murder.
file icon Court filing makes public my previously suppressed analysis of Paxil's effects 01/14/2003
Information on antidepressant-induced akathisia comes to light with court filing in Lacuzong case.
file icon How GlaxoSmithKline suppressed data on Paxil-induced akathisia 01/12/2002
Paxil Special Report II: Second special report in a series providing excerpts from Dr. Breggin's 1999 product liability report in the CA case of Lacuzong v. GlaxoSmithKline alleging that Paxil (paroxetine) caused a double murder and suicide. Ethical Psychology and Psychiatry 8 (2006) 91-100.
file icon Drug Company Suppressed Data on Paroxetine-Induced Stimulation 01/12/2001

Paxil Special Report III: The third special report in a series providing excerpts from Dr. Breggin's 1999 product liability report in the CA case of Lacuzong v. GlaxoSmithKline, alleging that Paxil (paroxetine) caused a double murder and suicide. Ethical Human Psychology and Psychiatry 8 (2006) 255-263.

file icon The Eli Lilly documents: Part I 01/14/2000
The Eli Lilly documents linking SSRIs with suicide and violence.
file icon The Eli Lilly documents: Part II 01/14/1999
The Eli Lilly documents linking SSRIs with suicide and violence.
<< Start < Prev 1 2 3 Next > End >>
Results 1 - 10 of 22

 

 

Dr. Peter Breggin and Colleagues
Launch New Reform Organization &
Annual Spring Conference
 

Peter R. Breggin, MD is no longer affiliated with the Center for the Study of Psychiatry, informally known as International Center for the Study of Psychiatry and Psychology, which he founded and led from 1972-2002, and Dr. Breggin will not participate in its conferences.   Dr. Breggin and his colleagues will hold their new annual spring conference April 8-10, 2011.  Details are available at http://www.empathictherapy.org.

 

 

WARNING!

Most psychiatric drugs can cause withdrawal reactions, sometimes including life-threatening emotional and physical withdrawal problems. In short, it is not only dangerous to start taking psychiatric drugs, it can also be dangerous to stop them. Withdrawal from psychiatric drugs should be done carefully under experienced clinical supervision. Methods for safely withdrawing from psychiatric drugs are discussed in Dr. Breggin's books, Brain-Disabling Treatments in Psychiatry: Drugs, Electroshock and the Psychopharmaceutical Complex (New York: Springer Publishing Company, 2008) and Medication Madness: The Role of Psychiatric Drugs in Cases of Violence, Suicide and Crime (New York: St. Martin's Press, 2008).